EDU 32 - ASTRO/SNO Joint Session: Current Multidisciplinary Management of Molecularly Defined IDH Mutant Grade 2 - 3 Glioma - Who, What, When, Why and How?
MODERATOR(S)
Roshan Prabhu, MD, MS - Levine Cancer Institute
session DESCRIPTION
The management of patients with grade 2 - 3 glioma has recently become even more complicated due to incorporation of molecular findings for pathologic diagnosis, changing criteria for who is considered high risk, and variability in the use and choice of chemotherapy with radiotherapy. This is an especially timely topic due to recent approval of the IDH inhibitor vorasidenib for IDH mutated low grade glioma. Additionally, there is little concrete direction in consensus guidelines for this patient population that tends to be younger and more heterogenous. This session is meant to provide a multidisciplinary overview (radiotherapy, neuro-oncology and neurosurgery) of the modern approach to molecular defined grade 2 - 3 glioma and answer the questions of "who, what, when, why and how" for this disease. We will discuss the molecular definitions for pathologic diagnosis based on the 2021 WHO criteria. A radiation oncologist will discuss indications and planning considerations for RT, as well as expected radiation toxicities and how that may alter management decisions. A neuro-oncologist will discuss the role of vorasidenib and indications and choice of PCV or temozolomide chemotherapy with RT. A neurosurgeon will discuss role of surgery and how that may differ based on molecular diagnosis and modern surgical techniques. Given the multidisciplinary nature of this disease, this will be a joint session with the Society of Neuro-Oncology (SNO) to provide critical perspectives to help inform radiation oncologists in their practice.
learning objectives
- Explain the indications for radiotherapy for patients with grade 2 - 3 glioma and describe optimal planning techniques, dose considerations and potential acute and late toxicities.
- Discuss the role of vorasidenib for IDH mutant grade 2-3 glioma and differentiate the options of PCV and temozolomide chemotherapy with RT.
- Describe the role of surgery for grade 2 - 3 glioma and how extent of resection decisions may be influenced by molecular findings.
Credits
| AMA PRA Category 1 Credits: | 1.00 |
Presentations
-
05:00pm - 06:00pm PT
ASTRO/SNO Joint Session: Current Multidisciplinary Management of Molecularly Defined IDH Mutant Grade 2 - 3 Glioma - Who, What, When, Why and How?
Speaker: Roshan Prabhu, MD, MS - Levine Cancer Institute, CHARLOTTE -
05:00pm - 05:02pm PT
Introductions
Speaker: Roshan Prabhu, MD, MS - Levine Cancer Institute, CHARLOTTE -
05:02pm - 05:17pm PT
Radiation Therapy for Grade 2-3 IDH-mutant Gliomas: Evidence, Innovation, and Evolving Practices
Speaker: Martin Tom, MD - The University of Texas MD Anderson Cancer Center, Houston -
05:17pm - 05:32pm PT
Updates in Systemic Therapies for IDH Mutated Grade 2 - 3 Gliomas
Speaker: Jennie Taylor, MD - UCSF, San Francisco -
05:32pm - 05:47pm PT
The Role of Surgery for IDH Mutant Gliomas: Evolving Indications in a Multidisciplinary Care Framework
Speaker: Sheila Singh, MD, PhD - McMaster University, Hamilton -
05:47pm - 06:00pm PT
Questions and Answers
Speaker: Roshan Prabhu, MD, MS - Levine Cancer Institute, CHARLOTTE